Zebrafish as a model system to screen radiation modifiers

Current Genomics

Volumn 8, Issue 6, 2007, Pages 360-369

  Hwang, Misun ^a   Yong, Cha ^a   Moretti, Luigi ^a   Lu, Bo ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Amifostine; ATM expression; DNA Repair Proteins; Nanoparticle DF 1; Radiotherapy

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AMIFOSTINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ATM PROTEIN; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DENDROFULLERENE; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; FULLERENE DERIVATIVE; MELPHALAN; MITOMYCIN; NUCLEAR PROTEIN; OLIGONUCLEOTIDE; PACLITAXEL; PROTEIN KU80; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

BIOLOGICAL MODEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; FLUSHING; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MONOTHERAPY; NEUROTOXICITY; NONHUMAN; PRURITUS; RADIATION EXPOSURE; RADIATION PROTECTION; RADIATION SICKNESS; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERTEBRATE; XEROSTOMIA; ZEBRA FISH;

DANIO RERIO; VERTEBRATA;

EID: 41549152936     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207783406497     Document Type: Review

References (186)

1. Driever, W., Solnica-Krezel, L., Schier, A. F., Neuhauss, S. C., Malicki, J., Stemple, D. L., Stainier, D. Y., Zwartkruis, F., Abdelilah, S., Rangini, Z., Belak, J., Boggs, C. A genetic screen for mutations affecting embryogenesis in zebrafish. Development 1996, 123: 37-46.
2. Haffter, P., Granato, M., Brand, M., Mullins, M. C., Hammerschmidt, M., Kane, D. A., Odenthal, J., van Eeden, F. J., Jiang, Y. J., Heisenberg, C. P., Kelsh, R. N., Furutani-Seiki, M., Vogelsang, E., Beuchle, D., Schach, U., Fabian, C., Nusslein-Volhard, C. The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development 1996, 123: 1-36.
3. Amatruda, J. F., Shepard, J. L., Stern, H. M., Zon, L. I. Zebrafish as a cancer model system. Cancer Cell 2002, 1: 229-31.
4. Grunwald, D. J., Eisen, J. S. Headwaters of the zebrafish - emergence of a new model vertebrate. Nat. Rev. Genet. 2002, 3: 717-24.
5. Stern, H. M., Zon, L. I. Cancer genetics and drug discovery in the zebrafish. Nat. Rev. Cancer 2003, 3: 533-9.
6. Zon, L. I. Zebrafish: a new model for human disease. Genome Res. 1999, 9: 99-100.
7. Trede, N. S., Langenau, D. M., Traver, D., Look, A. T., Zon, L. I. The use of zebrafish to understand immunity. Immunity 2004, 20: 367-79.
8. Zon, L. I., Peterson, R. T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug. Discov. 2005, 4: 35-44.
9. Brownlie, A., Donovan, A., Pratt, S. J., Paw, B. H., Oates, A. C., Brugnara, C., Witkowska, H. E., Sassa, S., Zon, L. I. Positional cloning of the zebrafish sauternes gene: a model for congenital sideroblastic anaemia. Nat. Genet. 1998, 20: 244-50.
10. Langenau, D. M., Traver, D., Ferrando, A. A., Kutok, J. L., Aster, J. C., Kanki, J. P., Lin, S., Prochownik, E., Trede, N. S., Zon, L. I., Look, A. T. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003, 299: 887-90.
11. Liu, T. X., Howlett, N. G., Deng, M., Langenau, D. M., Hsu, K., Rhodes, J., Kanki, J. P., D'Andrea, A. D., Look, A. T. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev. Cell. 2003, 5: 903-14.
12. Chen, E., Ekker, S. C. Zebrafish as a genomics research model. Curr. Pharm. Biotechnol. 2004, 5: 409-13.
13. Nasevicius, A., Ekker, S. C. The zebrafish as a novel system for functional genomics and therapeutic development applications. Curr. Opin. Mol. Ther. 2001, 3: 224-8.
14. Chakrabarti, S., Streisinger, G., Singer, F., Walker, C. Frequency of gamma-Ray Induced Specific Locus and Recessive Lethal Mutations in Mature Germ Cells of the Zebrafish, BRACHYDANIO RERIO. Genetics 1983, 103: 109-123.
15. Walker, C., Streisinger, G. Induction of Mutations by gamma-Rays in Pregonial Germ Cells of Zebrafish Embryos. Genetics 1983, 103: 125-136.
16. Schulte-Merker, S., van Eeden, F. J., Halpern, M. E., Kimmel, C. B., Nusslein-Volhard, C. no tail (ntl) is the zebrafish homologue of the mouse T (Brachyury) gene. Development 1994, 120: 1009-15.
17. Talbot, W. S., Trevarrow, B., Halpern, M. E., Melby, A. E., Farr, G., Postlethwait, J. H., Jowett, T., Kimmel, C. B., Kimelman, D. A homeobox gene essential for zebrafish notochord development. Nature 1995, 378: 150-7.
18. Kimmel, C. B. Genetics and early development of zebrafish. Trends Genet. 1989, 5: 283-8.
19. Johnson, S. L., Africa, D., Walker, C., Weston, J. A. Genetic control of adult pigment stripe development in zebrafish. Dev. Biol. 1995, 167: 27-33.
20. Postlethwait, J. H., Johnson, S. L., Midson, C. N., Talbot, W. S., Gates, M., Ballinger, E. W., Africa, D., Andrews, R., Carl, T., Eisen, J. S., et al. A genetic linkage map for the zebrafish. Science 1994, 264: 699-703.
21. Zoberi, I., Wasserman, T. H., Chao, K. S. A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers. Semin. Radiat. Oncol. 2002, 12: 14-7.
22. Fang, F. M., Tsai, W. L., Chen, H. C., Hsu, H. C., Hsiung, C. Y., Chien, C. Y., Ko, S. F. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007, 109: 313-21.
23. Ang, K. K. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol. 1998, 8: 230-6.
24. Weiss, J. F., Landauer, M. R. Radioprotection by antioxidants. Ann. N. Y. Acad. Sci. 2000, 899: 44-60.
25. Richardson, C. F., Schuster, D. I., Wilson, S. R. Synthesis and characterization of water-soluble amino fullerene derivatives. Org. Lett. 2000, 2: 1011-4.
26. Brettreich, M., Hirsch, A. A highly water-soluble dendro[60]fullerene. Tetrahedron. Lett. 1998: 2731-4.
27. Oberdorster, E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 2004, 112: 1058-62.
28. Ali, S. S., Hardt, J. I., Quick, K. L., Kim-Han, J. S., Erlanger, B. F., Huang, T. T., Epstein, C. J., Dugan, L. L. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic. Biol. Med. 2004, 37: 1191-202.
29. Aruoma, O. I., Halliwell, B., Gajewski, E., Dizdaroglu, M. Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. J. Biol. Chem. 1989, 264: 20509-12.
30. Frenkel, K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol. Ther. 1992, 53: 127-66.
31. Brand, M., Heisenberg, C. P., Warga, R. M., Pelegri, F., Karlstrom, R. O., Beuchle, D., Picker, A., Jiang, Y. J., Furutani-Seiki, M., van Eeden, F. J., Granato, M., Haffier, P., Hammerschmidt, M., Kane, D. A., Kelsh, R. N., Mullins, M. C., Odenthal, J., Nusslein-Volhard, C. Mutations affecting development of the midline and general body shape during zebrafish embryogenesis. Development 1996, 123: 129-42.
32. Stone, H. B., Coleman, C. N., Anscher, M. S., McBride, W. H. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003, 4: 529-36.
33. Patt HM, Tyree EB, RL., S. Cysteine protection against X irradiation. Science 1949, 110: 213-214.
34. Hall, E. J. Radioprotectors, Lippincott: Philadelphia, PA 2000.
35. Hensley, M. L., Schuchter, L. M., Lindley, C., Meropol, N. J., Cohen, G. I., Broder, G., Gradishar, W. J., Green, D. M., Langdon, R. J., Jr., Mitchell, R. B., Negrin, R., Szatrowski, T. P., Thigpen, J. T., Von Hoff, D., Wasserman, T. H., Winer, E. P., Pfister, D. G. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 1999, 17: 3333-55.
36. Yuhas, J. M. Protective drugs in cancer therapy: optimal clinical testing and future directions. Int. J. Radiat. Oncol. Biol. Phys. 1982, 8: 513-7.
37. McCulloch, W., Scheffler, B. J., Schein, P. S. New protective agents for bone marrow in cancer therapy. Cancer Invest. 1991, 9: 279-87.
38. Valeriote, F., Tolen, S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982, 42: 4330-1.
39. Wasserman, T. H., Phillips, T. L., Ross, G., Kane, L. J. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin. Trials 1981, 4: 3-6.
40. van der Vijgh, W. J., Peters, G. J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin. Oncol. 1994, 21: 2-7.
41. Yuhas, J. M. Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat. Res. 1970, 44: 621-8.
42. Wang, L. M., Wang, Q. W., Fernandes, D. J. Amifostine protects MRC-5 human lung fibroblasts from Taxol toxicity without reducing its cytotoxic effect against human non-small cell lung cancer cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1995, 36: A1712.
43. Poplin, E. A., LoRusso, P., Lokich, J. J., Gullo, J. J., Leming, P. D., Schulz, J. J., Veach, S. R., McCulloch, W., Baker, L., Schein, P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer. Chemother. Pharmacol. 1994, 33: 415-9.
44. Mehta, M., Storer, B., Larson, M. High response rate for advanced non-small cell lung cancer with amifostine, cisplatin, vinblastine and radiation. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1994, 13: A1167.
45. Buntzel, J., Glatzel, M., Mucke, R., Micke, O., Bruns, F. Influence of amifostine on late radiation-toxicity in head and neck cancer-a follow-up study. Anticancer Res. 2007, 27: 1953-6.
46. Veerasam, V., Phromratanapongse, P., Suntompong, N., Lorvid-haya, V., Sukthomya, V., Chitapanarux, I., Tesavibul, C., Swangsilpa, T., Khorprasert, C., Shotelersuk, K., Kongthanarat, Y., Panichevaluk, A., Chiewvit, S., Pusuwan, P., Aekmahachai, M., Ratchadara, S., Sirilipoche, S., Saengsuda, Y. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J. Med. Assoc. Thai. 2006, 89: 2056-67.
47. Komaki, R., Lee, J. S., Kaplan, B., Allen, P., Kelly, J. F., Liao, Z., Stevens, C. W., Fossella, F. V., Zinner, R., Papadimitrakopoulou, V., Khuri, F., Glisson, B., Pisters, K., Kurie, J., Herbst, R., Milas, L., Ro, J., Thames, H. D., Hong, W. K., Cox, J. D. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin. Radiat. Oncol. 2002, 12: 46-9.
48. Jatoi, A., Thomas, C. R., Jr. Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Semin. Radiat. Oncol. 2002, 12: 62-7.
49. Movsas, B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin. Radiat. Oncol. 2002, 12: 40-5.
50. Werner-Wasik, M., Axelrod, R. S., Friedland, D. P., Hauck, W., Rose, L. J., Chapman, A. E., Grubbs, S., Deshields, M., Curran, W. J. Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Semin. Radiat. Oncol. 2002, 12: 34-9.
51. Small, W., Jr. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review. Semin. Radiat. Oncol. 2002, 12: 68-74.
52. Werner-Wasik, M., Langer, C., Movsas, B. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Semin. Oncol. 2005, 32: S105-8.
53. Shaw, L. M., Bonner, H. S., Schuchter, L., Schiller, J., Lieberman, R. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin. Oncol. 1999, 26: 34-6.
54. Yuhas, J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980, 40: 1519-24.
55. Utley, J. F., Seaver, N., Newton, G. L., Fahey, R. C. Pharmacokinetics of WR- 1065 in mouse tissue following treatment with WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10: 1525-8.
56. Washburn, L. C., Rafter, J. J., Hayes, R. L. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat. Res. 1976, 66: 100-5.
57. Millar, J. L., McElwain, T. J., Clutterbuck, R. D., Wist, E. A. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721). Am. J. Clin. Oncol. 1982, 5: 321-8.
58. DiPaola, R. S., Schuchter, L. Neurologic protection by amifostine. Semin. Oncol. 1999, 26: 82-8.
59. Nieder, C., Andratschke, N. H., Wiedenmann, N., Molls, M. Prevention of radiation-induced central nervous system toxicity: a role for amifostine? Anticancer Res. 2004, 24: 3803-9.
60. Mori, T., Nikaido, O., Sugahara, T. Dephosphorylation of WR-2721 with mouse tissue homogenates. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10: 1529-31.
61. Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D., Ward, J. F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1985, 47: 23-7.
62. Travis, E. L. The oxygen dependence of protection by aminothiols: implications for normal tissues and solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10: 1495-501.
63. Yuhas, J. M., Afkal, S. M., Afkal, V. Variation in normal tissue responsiveness to WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10: 1537-9.
64. Savoye, C., Swenberg, C., Hugot, S., Sy, D., Sabattier, R., Charlier, M., Spotheim-Maurizot, M. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int. J. Radiat. Biol. 1997, 71: 193-202.
65. Peters, G. J., van der Vijgh, W. J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur. J. Cancer 1995, 31A Suppl 1: S1-7.
66. Durand, R. E. Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br. J. Cancer 1983, 47: 387-92.
67. -(dithiodi-2,1-ethanediyl)bis-1,3-propanediamine (WR-33278). Mutagenesis 1994, 9: 355-60.
68. Grdina, D. J., Guilford, W. H., Sigdestad, C. P., Giometti, C. S. Effects of radioprotectors on DNA damage and repair, proteins, and cell-cycle progression. Pharmacol. Ther. 1988, 39: 133-7.
69. Woloschak, G. E., Paunesku, T., Chang-Liu, C. M., Grdina, D. J. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res. 1995, 55: 4788-92.
70. Grdina, D. J., Kataoka, Y., Basic, I., Perrin, J. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 1992, 13: 811-4.
71. Curran, W. J. Radiation-induced toxicities: the role of radioprotectants. Semin. Radiat. Oncol. 1998, 8: 2-4.
72. McAleer, M. F., Davidson, C., Davidson, W. R., Yentzer, B., Farber, S. A., Rodeck, U., Dicker, A. P. Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61: 10-3.
73. Bladen, C. L., Lam, W. K., Dynan, W. S., Kozlowski, D. J. DNA damage response and Ku80 function in the vertebrate embryo. Nucleic Acids Res. 2005, 33: 3002-10.
74. Bang, D. W., Lee, J. H., Oh, H., Kim, S. R., Kim, T. H., Lee, Y. S., Lee, C. S., Kim, S. H. Dose-incidence relationships on the prenatal effects of gamma-radiation in mice. J. Vet. Sci. 2002, 3: 7-11.
75. Ching, S. V., Gillette, S. M., Powers, B. E., Roberts, S. M., Gillette, E. L., Withrow, S. J. Radiation-induced ocular injury in the dog: a histological study. Int. J. Radiat. Oncol. Biol. Phys. 1990, 19:321-8.
76. Hicks, S. P., D'Amato, C. J. Effects of radiation on development, especially of the nervous system. Am. J. Forensic. Med. Pathol. 1980, 1: 309-17.
77. Kimura, S. J., Ikui, H. Atomic-bomb radiation cataract. Case report with histopathologic study. Am. J. Ophthalmol. 1951, 34: 811-6.
78. Stewart, J. R., Fajardo, L. F. Radiation-induced heart disease. Clinical and experimental aspects. Radiol. Clin. North. Am. 1971, 9: 511-31.
79. Sun, X. Z., Inouye, M., Hayasaka, S., Takagishi, Y., Yamamura, H. Effects of different doses of gamma-radiation on the developing brain of mice. Environ. Med. 1995, 39: 113-6.
80. Wood, J. W., Johnson, K. G., Omori, Y. In utero exposure to the Hiroshima atomic bomb. An evaluation of head size and mental retardation: twenty years later. Pediatrics 1967, 39: 385-92.
81. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203: 253-310.
82. Russell, L. B., Russell, W. L. Pathways of radiation effects in the mother and the embryo. Cold. Spring. Harb. Symp. Quant. Biol. 1954, 19: 50-9.
83. Dekaban, A. S. Abnormalities in children exposed to x-radiation during various stages of gestation: tentative timetable of radiation injury to the human fetus. I. J. Nucl. Med. 1968, 9: 471-7.
84. Ikegami, R., Hunter, P., Yager, T. D. Developmental activation of the capability to undergo checkpoint-induced apoptosis in the early zebrafish embryo. Dev. Biol. 1999, 209: 409-33.
85. Upton, A. C., Odell, T. T., Jr., Sniffen, E. P. Influence of age at time of irradiation on induction of leukemia and ovarian tumors in RE mice. Proc. Soc. Exp. Biol. Med. 1960, 104: 769-72.
86. Sasaki, S., Kasuga, T., Sato, F., Kawashima, N. Late effects of fetal mice x-irradiated at middle or late intrauterine stage. Gann. 1978, 69: 167-77.
87. Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y., Kondo, S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat. Med. 1996, 2: 577-80.
88. Wang, B., Ohyama, H., Haginoya, K., Odaka, T., Yamada, T., Hayata, I. Prenatal radiation-induced limb defects mediated by Trp53-dependent apoptosis in mice. Radiat. Res. 2000, 154: 673-9.
89. Shimura, T., Toyoshima, M., Taga, M., Shiraishi, K., Uematsu, N., Inoue, M., Niwa, O. The novel surveillance mechanism of the Trp53-dependent s-phase checkpoint ensures chromosome damage repair and preimplantation-stage development of mouse embryos fertilized with x-irradiated sperm. Radiat. Res. 2002, 158: 735-42.
90. Uma Devi, P., Hossain, M. Induction of solid turnours in the Swiss albino mouse by low-dose foetal irradiation. Int. J. Radiat. Biol. 2000, 76: 95-9.
91. Giles, D., Hewitt, D., Stewart, A., Webb, J. Malignant disease in childhood and diagnostic irradiation in utero. Lancet 1956, 271: 447.
92. Stewart, A., Kneale, G. W. Changes in the cancer risk associated with obstetric radiography. Lancet 1968, 1: 104-7.
93. Stewart, A., Webb, J., Hewitt, D. A survey of childhood malignancies. Br. Med. J. 1958, 1: 1495-508.
94. Doll, R., Wakeford, R. Risk of childhood cancer from fetal irradiation. Br J Radiol. 1997, 70: 130-9.
95. Ward, J. F. Radiation mutagenesis: the initial DNA lesions responsible. Radiat. Res. 1995, 142: 362-8.
96. Houtgraaf, J. H., Versmissen, J., van der Giessen, W. J. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc. Revasc. Med. 2006, 7: 165-72.
97. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K., Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73: 39-85.
98. Rouse, J., Jackson, S. P. Interfaces between the detection, signaling, and repair of DNA damage. Science. 2002, 297: 547-51.
99. Melo, J., Toczyski, D. A unified view of the DNA-damage check-point. Curr. Opin. Cell. Biol. 2002, 14: 237-45.
100. Collis, S. J., DeWeese, T. L., Jeggo, P. A., Parker, A. R. The life and death of DNA-PK. Oncogene 2005, 24: 949-61.
101. Sonoda, E., Takata, M., Yamashita, Y. M., Morrison, C., Takeda, S. Homologous DNA recombination in vertebrate cells. Proc. Natl. Acad. Sci. USA 2001, 98: 8388-94.
102. Mills, K. D., Ferguson, D. O., Alt, F. W. The role of DNA breaks in genomic instability and tumorigenesis. Immunol. Rev. 2003, 194: 77-95.
103. Nyberg, K. A., Michelson, R. J., Putnam, C. W., Weinert, T. A. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 2002, 36: 617-56.
104. Hopfner, K. P., Putnam, C. D., Tainer, J. A. DNA double-strand break repair from head to tail. Curr. Opin. Struct. Biol. 2002, 12: 115-22.
105. Deng, C. X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006, 34: 1416-26.
106. Zhivotovsky, B., Kroemer, G. Apoptosis and genomic instability. Nat. Rev. Mol. Cell. Biol. 2004, 5: 752-62.
107. Dynan, W. S., Yoo, S. Interaction of Ku protein and DNA-dependent protein kinase catalytic subunit with nucleic acids. Nucleic Acids Res. 1998, 26: 1551-9.
108. Getts, R. C., Stamato, T. D. Absence of a Ku-like DNA end binding activity in the xrs double-strand DNA repair-deficient mutant. J. Biol. Chem. 1994, 269: 15981-4.
109. Sunder, V., Rathmell, W. K., Lieber, M. R., Chu, G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science 1994, 266: 288-91.
110. Taccioli, G. E., Gottlieb, T. M., Blunt, T., Priestley, A., Demengeot, J., Mizuta, R., Lehmann, A. R., Alt, F. W., Jackson, S. P., Jeggo, P. A. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 1994, 265: 1442-5.
111. Khanna, K. K., Jackson, S. P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 2001, 27: 247-54.
112. Wullimann, M. F., Knipp, S. Proliferation pattern changes in the zebrafish brain from embryonic through early postembryonic stages. Anat. Embryol. (Berl). 2000, 202: 385-400.
113. Hensey, C., Gautier, J. A developmental timer that regulates apoptosis at the onset of gastrulation. Mech. Dev. 1997, 69: 183-95.
114. Anderson, J. A., Lewellyn, A. L., Maller, J. L. Ionizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus. Mol. Biol. Cell. 1997, 8: 1195-206.
115. Stack, J. H., Newport, J. W. Developmentally regulated activation of apoptosis early in Xenopus gastrulation results in cyclin A degradation during interphase of the cell cycle. Development 1997, 124: 3185-95.
116. Bladden, C. L., Navarre, S., Dynan, W. S., Kozlowski, D. J. Expression of the Ku70 subunit (XRCC6) and protection from low dose ionizing radiation during zebrafish embryogenesis. Neurosci. Lett. 2007, 422: 97-102.
117. Qin, Q., Patil, K., Sharma, S. C. The role of Bax-inhibiting peptide in retinal ganglion cell apoptosis after optic nerve transection. Neurosci. Lett. 2004, 372: 17-21.
118. Sawada, M., Sun, W., Hayes, P., Leskov, K., Boothman, D. A., Matsuyama, S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell. Biol. 2003, 5: 320-9.
119. Subramanian, C., Opipari, A. W., Jr., Bian, X., Castle, V. P., Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102: 4842-7.
120. Chen, G., Lee, E. The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J. Biol. Chem. 1996, 271: 33693-7.
121. Scott, S. P., Zhang, N., Khanna, K. K., Khromykh, A., Hobson, K., Waiters, D., Lavin, M. F. Cloning and expression of the ataxia-telangiectasia gene in baculovirus. Biochem. Biophys. Res. Commun. 1998, 245: 144-8.
122. Kurz, E. U., Lees-Miller, S. P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair. (Amst). 2004, 3: 889-900.
123. Kitagawa, R., Kastan, M. B. The ATM-dependent DNA damage signaling pathway. Cold. Spring. Harb. Symp. Quant. Biol. 2005, 70: 99-109.
124. Bakkenist, C. J., Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421: 499-506.
125. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281: 1674-7.
126. Cortez, D., Wang, Y., Qin, J., Elledge, S. J. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks. Science 1999, 286: 1162-6.
127. Kastan, M. B., Lim, D. S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell. Biol. 2000, 1:179-86.
128. Kishi, S., Lu, K. P. A critical role for Pin2/TRF1 in ATM-dependent regulation. Inhibition of Pin2/TRF1 function complements telomere shortening, radio sensitivity, and the G(2)/M checkpoint defect of ataxia-telangiectasia cells. J. Biol. Chem. 2002, 277: 7420-9.
129. Kishi, S., Zhou, X. Z., Ziv, Y., Khoo, C., Hill, D. E., Shiloh, Y., Lu, K. P. Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks. J. Biol. Chem. 2001, 276: 29282-91.
130. Pandita, T. K. ATM function and telomere stability. Oncogene. 2002, 21: 611-8.
131. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3: 155-68.
132. Lavin, M. F., Shiloh, Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 1997, 15: 177-202.
133. McKinnon, P. J. ATM and ataxia telangiectasia. EMBO Rep. 2004, 5: 772-6.
134. Xu, Y., Ashley, T., Brainerd, E. E., Bronson, R. T., Meyn, M. S., Baltimore, D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 1996, 10: 2411-22.
135. Herzog, K. H., Chong, M. J., Kapsetaki, M., Morgan, J. I., McKinnon, P. J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998, 280: 1089-91.
136. Elson, A., Wang, Y., Daugherty, C. J., Morton, C. C., Zhou, F., Campos-Torres, J., Leder, P. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA 1996, 93: 13084-9.
137. Soares, H. D., Morgan, J. I., McKinnon, P. J. Atm expression patterns suggest a contribution from the peripheral nervous system to the phenotype of ataxia-telangiectasia. Neuroscience 1998, 86: 1045-54.
138. Hensey, C., Robertson, K., Gautier, J. Expression and subcellular localization of X-ATM during early Xenopus development. Dev. Genes Evol. 2000, 210: 467-9.
139. Allen, D. M., van Praag, H., Ray, J., Weaver, Z., Winrow, C. J., Carter, T. A., Braquet, R., Harrington, E., Ried, T., Brown, K. D., Gage, F. H., Barlow, C. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev. 2001, 15: 554-66.
140. Barlow, C., Ribaut-Barassin, C., Zwingman, T. A., Pope, A. J., Brown, K. D., Owens, J. W., Larson, D., Harrington, E. A., Haeberle, A. M., Mariani, J., Eckhaus, M., Herrup, K., Bailly, Y., Wynshaw-Boris, A. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl. Acad. Sci. USA 2000, 97: 871-6.
141. Lee, Y., Chong, M. J., McKinnon, P. J. Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J. Neurosci. 2001, 21: 6687-93.
142. Lee, Y., McKinnon, P. J. ATM dependent apoptosis in the nervous system. Apoptosis 2000, 5: 523-9.
143. Miller, H. L., Lee, Y., Zhao, J., Chong, M. J., McKinnon, P. J. Atm and c-Ab1 cooperate in the response to genotoxic stress during nervous system development. Brain Res. Dev. Brain Res. 2003, 145: 31-8.
144. Morgan, S. E., Lovly, C., Pandita, T. K., Shiloh, Y., Kastan, M. B. Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 1997, 17:2020-9.
145. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998, 281: 1677-9.
146. Chenevix-Trench, G., Spurdle, A. B., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M. A., Scott, C., Pupo, G. M., Dork, T., Bendix, R., Kirk, J., Tucker, K., McCredie, M. R., Hopper, J. L., Sambrook, J., Mann, G. J., Khanna, K. K. Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst. 2002, 94: 205-15.
147. Gilad, S., Khosravi, R., Shkedy, D., Uziel, T., Ziv, Y., Savitsky, K., Rotman, G., Smith, S., Chessa, L., Jorgensen, T. J., Harnik, R., Frydman, M., Sanal, O., Portnoi, S., Goldwicz, Z., Jaspers, N. G., Gatti, R. A., Lenoir, G., Lavin, M. F., Tatsumi, K., Wegner, R. D., Shiloh, Y., Bar-Shira, A. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 1996, 5: 433-9.
148. Stankovic, T., Kidd, A. M., Sutcliffe, A., McGuire, G. M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A. R., Easton, D. F., Lennox, G. G., Haites, N., Byrd, P. J., Taylor, A. M. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 1998, 62: 334-45.
149. Garg, R., Geng, C. D., Miller, J. L., Callens, S., Tang, X., Appel, B., Xu, B. Molecular cloning and characterization of the catalytic domain of zebrafish homologue of the ataxia-telangiectasia mutated gene. Mol. Cancer Res. 2004, 2: 348-53.
150. Imamura, S., Kishi, S. Molecular cloning and functional characterization of zebrafish ATM. Int. J. Biochem. Cell Biol. 2005, 37: 1105-16.
151. Laposa, R. R., Henderson, J. T., Xu, E., Wells, P. G. Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM. Faseb J. 2004, 18: 896-8.
152. Till, J. E., Mc, C. E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 1961, 14: 213-22.
153. Becker, A. J., Mc, C. E., Till, J. E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197: 452-4.
154. Siminovitch, L., McCulloch, E. A., Till, J. E. The Distribution of Colony-Forming Cells among Spleen Colonies. J. Cell. Physiol. 1963, 62: 327-36.
155. Wu, A. M., Till, J. E., Siminovitch, L., McCulloch, E. A. A cytological study of the capacity for differentiation of normal hemopoietic colony-forming cells. J. Cell. Physiol. 1967, 69: 177-84.
156. Lorenz, E., Uphoff, D., Reid, T. R., Shelton, E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J. Natl. Cancer Inst. 1951, 12: 197-201.
157. Congdon, C. C., Uphoff, D., Lorenz, E. Modification of acute irradiation injury in mice and guinea pigs by injection of bone marrow, a histopathologic study. J. Natl. Cancer Inst. 1952, 13: 73-107.
158. Na Nakorn, T., Traver, D., Weissman, I. L., Akashi, K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J. Clin. Invest. 2002, 109: 1579-85.
159. Traver, D., Herbomel, P., Patton, E. E., Murphey, R. D., Yoder, J. A., Litman, G. W., Catic, A., Amemiya, C. T., Zon, L. I., Trede, N. S. The zebrafish as a model organism to study development of the immune system. Adv. Immunol. 2003, 81: 253-330.
160. Lindsley, D. L., Odell, T. T., Jr., Tausche, F. G. Implantation of functional erythropoietic elements following total-body irradiation. Proc. Soc. Exp. Biol. Med. 1955, 90: 512-5.
161. Nowell, P. C., Cole, L. J., Habermeyer, J. G., Roan, P. L. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res. 1956, 16: 258-61.
162. Ford, C. E., Hamerton, J. L., Barnes, D. W., Loutit, J. F. Cytological identification of radiation-chimaeras. Nature 1956, 177: 452-4.
163. Makinodan, T. Circulating rat cells in lethally irradiated mice protected with rat bone marrow. Proc. Soc. Exp. Biol. Med. 1956, 92: 174-9.
164. Jacobson, L. O., Marks, E. K., Robson, M. J., Gaston, E., Zirkle, R. E. The effect of spleen protection on mortality following X-irradiation. J. Lab. Clin. Med. 1949, 34: 1538-1543.
165. Jacobson, L. O., Simmons, E. L., Marks, E. K., Gaston, E. O., Robson, M. J., Eldredge, J. H. Further studies on recovery from radiation injury. J. Lab. Clin. Med. 1951, 37: 683-97.
166. Bacq, Z. M., Alexander, P. Fundamentals of Radiobiology, Pergamon Press: New York, NY 1961.
167. Hevesy, G. C., Forssberg, A. G., Abbatt, J. D. Advances in Radiobiology, Olivier and Boyd: Edinburgh, Scotland. 1957.
168. Hyodo, Y. Effect of X-Irradiation on the Intestinal Epithelium of the Goldfish Carassius Auratus. Ii. Influence of Temperature on the Development of Histopathological Changes in the Intestine. Radiat. Res. 1965, 24: 133-41.
169. Atland, P. D., Brace, K. C. Red cell lifespan in the turtle and pad. Am. J. Physiol. 1962, 203: 1188-1190.
170. Schmidt-Ullrich, R. K., Contessa, J. N., Lammering, G., Amorino, G., Lin, P. S. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 2003, 22: 5855-65.
171. McAleer, M. F., Duffy, K. T., Davidson, W. R., Kari, G., Dicker, A. P., Rodeck, U., Wickstrom, E. Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66: 546-51.
172. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA 1996, 93: 2735-40.
173. Newcomb, E. W. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004, 15: 411-9.
174. Blagosklonny, M. V. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004, 3: 1537-42.
175. Hall, E. J. Radiation, the two-edged sword: cancer risks at high and low doses. Cancer J. 2000, 6: 343-50.
176. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis,
177. Mason, K. A., Hunter, N. R., Raju, U., Ariga, H., Husain, A., Valdecanas, D., Neal, R., Ang, K. K., Milas, L. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59: 1181-9.
178. Raju, U., Nakata, E., Mason, K. A., Ang, K. K., Milas, L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 2003, 63: 3263-7.
179. Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Tsurumaru, M. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Dis. Esophagus 2004, 17: 338-44.
180. Camphausen, K., Brady, K. J., Burgan, W. E., Cerra, M. A., Russell, J. S., Bull, E. E., Tofilon, P. J. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol. Cancer Ther. 2004, 3: 409-16.
181. Jung, C., Motwani, M., Kortmansky, J., Sirotnak, F. M., She, Y., Gonen, M., Haimovitz-Friedman, A., Schwartz, G. K. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin. Cancer Res. 2003, 9: 6052-61.
182. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998, 92: 3804-16.
183. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs 1999, 17: 313-20.
184. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 2000, 18: 371-5.
185. Tan, A. R., Yang, X., Berman, A., Zhai, S., Sparreboom, A., Parr, A. L., Chow, C., Brahim, J. S., Steinberg, S. M., Figg, W. D., Swain, S. M. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10: 5038-47.
186. Bible, K. C., Lensing, J. L., Nelson, S. A., Lee, Y. K., Reid, J. M., Ames, M. M., Isham, C. R., Piens, J., Rubin, S. L., Rubin, J., Kaufmann, S. H., Atherton, P. J., Sloan, J. A., Daiss, M. K., Adjei, A. A., Erlichman, C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin. Cancer Res. 2005, 11: 5935-41.